

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
01 February 2024 (01.02.2024)



(10) International Publication Number
WO 2024/026122 A2

- (51) **International Patent Classification:**
C12N 15/11 (2006.01) *A61K 31/712* (2006.01)
- (21) **International Application Number:**
PCT/US2023/029040
- (22) **International Filing Date:**
28 July 2023 (28.07.2023)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
63/369,845 29 July 2022 (29.07.2022) US
- (71) **Applicant:** **STOKE THERAPEUTICS, INC.** [US/US];
45 Wiggins Avenue, Bedford, Massachusetts 01730 (US).
- (72) **Inventors:** **AZNAREZ, Isabel**; c/o Stoke Therapeutics,
Inc., 45 Wiggins Avenue, Bedford, Massachusetts 01730
(US). **HAN, Zhou**; c/o Stoke Therapeutics, Inc., 45
Wiggins Avenue, Bedford, Massachusetts 01730 (US).
CHRISTIANSEN, Anne; c/o Stoke Therapeutics, Inc.,
45 Wiggins Avenue, Bedford, Massachusetts 01730 (US).
MEENA, Meena; c/o Stoke Therapeutics, Inc., 45 Wig-
gins Avenue, Bedford, Massachusetts 01730 (US). **TICHO,**
Baruch; c/o Stoke Therapeutics, Inc., 45 Wiggins Av-
enue, Bedford, Massachusetts 01730 (US). **LIAU, Gene**; c/

o Stoke Therapeutics, Inc., 45 Wiggins Avenue, Bedford,
Massachusetts 01730 (US).

(74) **Agent:** **CHANDRAMOULI, Srividya**; Wilson Sonsini
Goodrich & Rosati, 650 Page Mill Road, Palo Alto, Cali-
fornia 94304 (US).

(81) **Designated States** (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) **Designated States** (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,

(54) **Title:** COMPOUNDS FOR TREATMENT OF CONDITIONS AND DISEASES




FIG. 1C

(57) **Abstract:** Compounds are provided herein that can promote expression of a specific gene, *SCN1A*. In some aspects, provided herein are compositions, methods, and kits relating to the compounds disclosed herein. In some aspects, compounds provided herein can target the alternative splicing events in *SCN1A* gene and can modulate the expression level of functional proteins in Dravet Syndrome patients and/or inhibit aberrant protein expression. Such compounds can be used to treat a condition caused by *SCN1A*, *SCN8A* or *SCN5A* protein deficiency.

[Continued on next page]

SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

- *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*